Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

Sudhakiranmayi Kuravi, M.S., Janice Cheng, MD, Kishore Polireddy, PhD, Gabrielle Fangman, B.S., Roy A Jensen, MD, Tara L. Lin, MD, Siddhartha Ganguly, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2019) 134 (Supplement_1): 2865.

https://doi.org/10.1182/blood-2019-130633

Published: 2019

Journal Articles

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

Sudhakiranmayi Kuravi, M.S., Elizabeth Parrott, M.A., Siddhartha Ganguly, MD, Anusha Vallurupalli, MD, Yogenthiran Saunthararajah, MD, Brian S Blagg, PhD, Jensen Roy, MD, Joseph P. McGuirk, DO, Ramesh Balusu, PhD

Blood (2017) 130 (Supplement 1): 2758.

https://doi.org/10.1182/blood.V130.Suppl_1.2758.2758

Published: 2017

Journal Articles

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

Xiaorong Gu, PhD, Quteba Ebrahem, MD, Reda Z. Mahfouz, MD PhD, Metis Hasipek, PhD, Francis Enane, PhD, Tomas Radivoyevitch, Nicolas Rapin, PhDMSc, Bartlomiej P. Przychodzen, MSc, Ramesh Balusu, PhD, Claudiu V Cotta, David Wald, MD PhD, Zhenbo Hu, MD PhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, MD, Hetty E. Carraway, MD MBA, Jaroslaw P. Maciejewski, PhD MD FACP, Babal K Jha, PhD, Yogenthiran Saunthararajah, MD

Blood (2017) 130 (Supplement 1): 878.

https://doi.org/10.1182/blood.V130.Suppl_1.878.878

Published: 2017

Journal Articles

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

Sudhakiranmayi Kuravi, M.S., Preethi Kunchala, M.S., Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Yogen Saunthararajah, MD, Kojo S. J. Elenitoba-Johnson, MD, Jensen Roy, MD, Joseph McGuirk, DO, Ramesh Balusu, PhD

Blood (2016) 128 (22): 4127.

https://doi.org/10.1182/blood.V128.22.4127.4127

Published: 2016

Journal Articles

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Xiaorong Gu, PhD, Reda Z. Mahfouz, MD, PhD, Quteba Ebrahem, Francis Enane, Tomas Radivoyevitch, PhD, Michael J. Clemente, M.S., Bartlomiej P Przychodzen, MSc, Zhenbo Hu, MD PhD, Ramesh Balusu, PhD, Claudiu V. Cotta, MD, David N. Wald, MDPhD, Yosef Landesman, PhD, Maria Paola Martelli, MD PhD, Brunangelo Falini, Jaroslaw P Maciejewski, MD PhD FACP, Yogenthiran Saunthararajah, MD

Blood (2016) 128 (22): 444.

https://doi.org/10.1182/blood.V128.22.444.444

Published: 2016

Journal Articles

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Warren Fiskus, PhD, Sunil Sharma, MD, Rekha Rao, PhD, Ramesh Balusu, PhD, Sreedhar Venkannagari, PhD, Stacey Hembruff, MS, Siddhartha Ganguly, MD, Eduardo M. Sotomayor, Jianguo Tao, MD, PhD, David J. Bearss, PhD, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 2429.

https://doi.org/10.1182/blood.V118.21.2429.2429

Published: 2011

Journal Articles

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Ramesh Balusu, PhD, Josiah Cox, Stacey Hembruff, MS, Warren Fiskus, BSc, PhD, Rekha Rao, PhD, Uma Mudunuru, MS, Ruben Reyes, MD, Siddhartha Ganguly, MD, Sunil Abhyankar, MD, Heather Male, MD, Allan Fleming, MD, Casey B Williams, Pharm.D., Joseph McGuirk, DO, Kapil N. Bhalla, MD

Blood (2011) 118 (21): 733.

https://doi.org/10.1182/blood.V118.21.733.733

Published: 2011

NARROW

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Email alerts

ASH Publications

American Society of Hematology

Preclinical Evaluation of Gilteritinib on NPM1-ALK Driven Anaplastic Large Cell Lymphoma Cells

CDC37 As a Novel Target for the Treatment of NPM1-ALK Expressing Anaplastic Large Cell Lymphomas

The Mechanisms By Which Mutant-NPM1 Uncouples Differentiation from Proliferation Are Reversed By Several Drugs, Enabling Rational Multi-Component Non-Cytotoxic Differentiation Therapy

NPM1-TYK2 Fusion Is an Oncogene and a Novel HSP90-Client Protein

The Mechanism By Which Mutant Nucleophosmin (NPM1) Creates Leukemic Self-Renewal Is Readily Reversed

Combined Targeting of Chromatin Modifying Enzymes LSD1, EZH2 and Histone Deacetylases (HDACs) Has Superior Efficacy Against Human Mantle Cell Lymphoma Cells

Targeting Mutant Nucleophosmin 1 (NPM1) Induces Differentiation, Loss of Survival and Sensitizes AML Cells to All-Trans Retinoic Acid, Cytarbine and FLT3 Antagonists

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only